Eflornithine: all 42 studies that test it
Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.
- Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade GliomasRecruitingNCT07468136Phase 1/2
- DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or OsteosarcomaRecruitingNCT06892678Phase 1/2
- Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate CancerRecruitingNCT06059118Phase 2
- Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or AstrocytomaRecruitingNCT05879367Phase 1
- Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade GliomaRecruitingNCT05717153Early Phase 1
- DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed MedulloblastomaRecruitingNCT04696029Phase 2
- Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory NeuroblastomaActive, not recruitingNCT03794349Phase 2Results posted
- Chemoprevention of Gastric CarcinogenesisCompletedNCT02794428Phase 2Results posted
- Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in RemissionCompletedNCT02395666Phase 2Results posted
- Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory NeuroblastomaCompletedNCT02139397Phase 1/2Results posted
- Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)CompletedNCT01483144Phase 3Results posted
- Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With EtoposideCompletedNCT01059071Phase 1Results posted
- Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal CancerCompletedNCT00983580Phase 2Results posted
- Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged SkinCompletedNCT00601640Phase 2Results posted
- Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon PolypsCompletedNCT00118365Phase 3Results posted
- Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous PolyposisCompletedNCT00033371Phase 2Results posted
- Eflornithine in Treating Patients At High Risk of Developing Prostate CancerCompletedNCT00006101Phase 2Results posted
- Randomized Split-Face Controlled Study to Evaluate the Effectiveness of Topical Eflornithine 9.58% + Hydroquinone 4% + Fluocinolone 0.01% as Compared to Topical Tretinoin 0.05% + Hydroquinone 4% + Fluocinolone 0.01% for the Treatment of MelasmaCompletedNCT07876323Phase 2
- Efficacy of Eflornithine Hydrochloride Cream in the Treatment of Melasma: A Randomized, Double-blinded, Split-face Controlled StudyCompletedNCT06957834Phase 2
- Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)SuspendedNCT06219174Phase 1/2
- TArgeting Type 1 Diabetes Using POLyamines (TADPOL)Active, not recruitingNCT05594563Phase 2
- Oral AMXT 1501 Dicaprate in Combination With IV DFMOTerminatedNCT05500508Phase 1/2
- Eflornithine (DFMO) and Etoposide for Relapsed/Refractory NeuroblastomaActive, not recruitingNCT04301843Phase 2
- Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin CancerCompletedNCT04091022Phase 2
- Oral AMXT 1501 Dicaprate in Combination With DFMOCompletedNCT03536728Phase 1
- Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) PatientsStatus unknownNCT02796261Phase 3
- Neuroblastoma Maintenance Therapy TrialActive, not recruitingNCT02679144Phase 2
- DFMO in Children With Type 1 DiabetesCompletedNCT02384889Phase 1
- N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/TopotecanCompletedNCT02030964Phase 1
- Treatment With Topical Eflornithin After Laser Treatment in Women With Facial HirsutismCompletedNCT01817894Phase 4
- Urinary Biomarker Study With Sulindac and DifluoromethylornithineWithdrawnNCT01636128Phase 2
- S0820, Adenoma and Second Primary Prevention TrialActive, not recruitingNCT01349881Phase 3
- A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)WithdrawnNCT01245816Phase 3
- Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant RecipientsCompletedNCT00204789Phase 2
- Evaluation of Eflornithine on Facial and Forearm SkinCompletedNCT00152048Phase 4
- Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African TrypanosomiasisCompletedNCT00146627Phase 3
- Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical ProstatectomyCompletedNCT00086736Phase 2
- Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic KeratosisCompletedNCT00021294Phase 2
- Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial NeoplasiaCompletedNCT00006079Phase 2
- Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin CancerCompletedNCT00005884Phase 3
- Eflornithine in Treating Patients With Bladder CancerCompletedNCT00003814Phase 3
- Eflornithine to Prevent Cancer in Patients With Barrett's EsophagusCompletedNCT00003076Phase 2